拉米夫定联合扶正化瘀胶囊治疗活动性肝硬化54例

Lamivudine Combined with Fuzhenghuayu Capsule for Treating Active Hepatic Cirrhosis in 54 Cases

目的探讨拉米夫定联合扶正化瘀胶囊治疗乙型肝炎病毒所致活动性肝硬化的疗效。方法将108例患者随机均分成两组,对照组54例仅口服拉米夫定片100 mg/d;治疗组加服扶正化瘀胶囊5粒/次、每日3次。总疗程均为24个月。观察临床表现以及肝功能和肝纤维化变化、不良反应。结果治疗后肝纤维化指标Ⅲ型前胶原(PCⅢ),治疗组为(228.6±114.4)μg/L,对照组为(331.5±98.2)μg/L,P<0.05;透明质酸(HA)水平治疗组为(138.3±120.42)μg/L,对照组为(278.2±100.1)μg/L,P<0.05;肝功能改善治疗组显著好于对照组;治疗组未发现不良反应。结论拉米夫定联合扶正化瘀胶囊治疗活动性肝硬化,能明显改善肝纤维化程度和肝功能,且安全可靠。

Objective To study the effect of lamivudine combined with Fuzhenghuayu Capsule for treating active hepatic cirrhosis caused by HBV.Methods 108 cases of active hepatic cirrhosis were randomly divided into two groups.The control group was treated with only oral lamivudine 100 mg per day,while the treatment group was added oral Fuzhenghuayu Capsule on the base of control group treatment,5 capsules once,3 times perday.The total treatment course was 24 months in the two groups.The clinical manifestations,changes of liver function and hepatic fibrosis,and adverse reactions were observed and compared between the two groups.Results After 24 months treatment,serum PClII levels were（331.5±98.2）μg/L in the control group and（228.6±114.4） μg/L in the treatment group,showing statistical difference（P 0.05）.The hyaluronic acid（HA） levels were（278.2±100.1）μg/L in the control group and（138.3±120.42）μg/L in the treatment group with statistical difference between them（P 0.05）.Compared with the control group,the liver function in the treatment group was improved better.No adverse reactions were found.Conclusion Lamivudine combined with Fuzhenghuayu Capsule for treating active hepatic cirrhosis can obviously improve the degree of liver fibrosis and liver function with safety and reliability